Document and Entity Information Document - shares	3 Months Ended
Document and Entity Information Document - shares	Mar. 31, 2017	Apr. 24, 2017
Entity Information [Line Items]
Entity Registrant Name	ALEXION PHARMACEUTICALS INC
Entity Central Index Key	0000899866
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		224,556,542

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 713	$ 966
Marketable securities	749	327
Trade accounts receivable, net	660	650
Inventories	396	375
Prepaid expenses and other current assets	215	260
Total current assets	2,733	2,578
Property, plant and equipment, net	1,138	1,036
Intangible assets, net	4,223	4,303
Goodwill	5,037	5,037
Other assets	304	299
Total assets	13,435	13,253
Liabilities and Stockholders' Equity
Accounts payable	61	64
Accrued expenses	546	508
Deferred revenue	16	37
Current portion of long-term debt	167	167
Current portion of contingent consideration	25	24
Other current liabilities	22	23
Total current liabilities	837	823
Long-term debt, less current portion	2,846	2,888
Contingent consideration	132	129
Facility lease obligation	270	233
Deferred Tax Liabilities	384	396
Other liabilities	110	90
Total liabilities	4,579	4,559
Commitments and contingencies (Note 16)
Stockholders' Equity:
Common stock, $0.0001 par value; 290 shares authorized; 233 and 232 shares issued as of March 31, 2017 and December 31, 2016, respectively	0	0
Additional paid-in capital	8,060	7,957
Treasury stock, at cost, 9 and 8 shares as of March 31, 2017 and December 31, 2016, respectively	(1,209)	(1,141)
Accumulated other comprehensive income	36	60
Retained earnings	1,969	1,818
Total stockholders' equity	8,856	8,694
Total liabilities and stockholders' equity	$ 13,435	$ 13,253

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	290	290
Common stock, shares issued	233	232
Treasury Stock, Shares	9	8

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net product sales	$ 869	$ 700
Other Revenue	1	1
Revenue, Net	870	701
Cost of sales	69	59
Operating expenses:
Research and development	219	176
Selling, general and administrative	262	233
Amortization of Intangible Assets Acquired	80	80
Change in fair value of contingent consideration	4	(15)
Acquisition-related costs	0	1
Restructuring expenses	24	1
Total operating expenses	589	476
Operating income	212	166
Other income and expense:
Investment income	4	1
Interest expense	(24)	(24)
Other income	2	0
Income before income taxes	194	143
Income tax expense	24	51
Net income	$ 170	$ 92
Earnings per common share
Basic	$ 0.76	$ 0.41
Diluted	$ 0.75	$ 0.41
Shares used in computing earnings per common share
Basic	224	225
Diluted	226	227

Condensed Consolidated Statements of Comprehensive Income Statement - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net income	$ 170	$ 92
Foreign currency translation	3	2
Unrealized gains on marketable securities	1	2
Unrealized gains on pension obligation	0	2
Unrealized losses on hedging activities, net of tax of $(15), and $(36), respectively	(28)	(64)
Net other comprehensive income (loss)	(24)	(58)
Comprehensive income	$ 146	$ 34

Condensed Consolidated Statements of Comprehensive Income Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income (Parenthetical) [Abstract]
Unrealized losses on hedging activities - tax effect	$ (15)	$ (36)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 170	$ 92
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	99	97
Change in fair value of contingent consideration	4	(15)
Share-based compensation expense	54	57
Deferred taxes	(1)	29
Unrealized foreign currency gain	(15)	(14)
Unrealized loss on forward contracts	11	17
Other	2	1
Changes in operating assets and liabilities:
Accounts receivable	(3)	(37)
Inventories	(19)	(4)
Prepaid expenses and other assets	(13)	(65)
Accounts payable, accrued expenses and other liabilities	39	(42)
Deferred revenue	(20)	58
Net cash provided by operating activities	308	174
Cash flows from investing activities:
Purchases of available-for-sale securities	(700)	(208)
Proceeds from maturity or sale of available-for-sale securities	282	269
Purchases of trading securities	(3)	(3)
Purchases of property, plant and equipment	(75)	(64)
Net cash used in investing activities	(495)	(6)
Proceeds from sale of trading securities	1	0
Cash flows from financing activities:
Payments on term loan	(44)	(175)
Repurchase of Common Stock	(68)	(297)
Net proceeds from the exercise of stock options	47	4
Other	(4)	(4)
Net cash used in financing activities	(69)	(472)
Effect of exchange rate changes on cash	3	4
Net change in cash and cash equivalents	(253)	(300)
Cash and cash equivalents at beginning of period	966	1,010
Cash and cash equivalents at end of period	713
Supplemental cash flow disclosures from investing and financing activities:
Capitalization of construction costs related to facility lease obligations	39	26
Accrued expenses for purchases of property, plant and equipment	$ 30	$ 25

Business	3 Months Ended
Business	Mar. 31, 2017
Business [Abstract]
Business	Business Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a biopharmaceutical company focused on serving patients with devastating and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. In our complement franchise, Soliris® is the first and only therapy approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS are two disorders resulting from chronic uncontrolled activation of the complement component of the immune system. In our metabolic franchise, we market Strensiq® for the treatment of patients with hypophosphatasia (HPP) and Kanuma® for the treatment of patients with lysosomal acid lipase deficiency (LAL-D). HPP is an ultra-rare genetic disease characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities. LAL-D is a serious, life threatening ultra-rare disease in which genetic mutations result in decreased activity of the lysosomal acid lipase (LAL) enzyme leading to marked accumulation of lipids in vital organs, blood vessels and other tissues. We initiated sales of Strensiq and Kanuma in the third quarter 2015. We are also evaluating additional potential indications for eculizumab in other severe and devastating diseases in which uncontrolled complement activation is the underlying mechanism, and we are progressing in various stages of development with additional product candidates as potential treatments for patients with devastating and ultra-rare disorders.

Basis of Presentation and Principles Of Consolidation	3 Months Ended
Basis of Presentation and Principles Of Consolidation	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2016. In our opinion, the accompanying unaudited consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet data as of December 31, 2016 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2016 included in our Annual Report on Form 10-K. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results to be expected for the full year. The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense. The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016. Change in Accounting Estimates We have historically deferred revenue recognition for sales to certain international customers, mainly distributors, until the product was received by the end customer due to various factors, including our inability to estimate product returns. On a regular basis, we review revenue arrangements, including our distributor relationships, to determine whether any changes in these arrangements or historical experience with these customers have an impact on revenue recognition. In the first quarter 2017, we determined that we had sufficient sales experience with certain customers to estimate product returns from such customers. We accounted for this prospectively as a change in estimate and began to recognize revenue for these customers when title to the product and the associated risk of loss passed to the customer. Some customers may purchase larger quantities of product less frequently, which may result in revenue fluctuations from quarter to quarter. We do not believe these buying patterns increase the risk of product returns or our ability to estimate such returns. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. Entities may elect to early adopt the standard for annual periods beginning after December 15, 2016. We currently anticipate adopting the standard using the modified retrospective method. We do not expect the implementation of this new standard to have a material impact on our financial position and results of operations. In February 2016, the FASB issued a new standard requiring that the rights and obligations arising from leases be recognized on the balance sheet by recording a right-of-use asset and corresponding lease liability. The new standard also requires qualitative and quantitative disclosures to understand the amount, timing, and uncertainty of cash flows arising from leases, as well as significant management estimates utilized. The standard is effective for interim and annual periods beginning after December 15, 2018 and requires a modified retrospective adoption. We are currently assessing the impact of this standard on our financial condition and results of operations. In March 2016, the FASB issued a new standard intended to simplify certain aspects of the accounting for employee share-based payments. We elected to early adopt this standard in 2016. One aspect of the standard requires an entity to recognize all excess tax benefits and deficiencies associated with stock-based compensation as a reduction or increase to tax expense in the income statement. Previously, such amounts were recognized in additional paid-in capital. The amendments also require recognition of excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. Furthermore, the amendment requires that excess tax benefits be classified as an operating activity in the statement of cash flows instead of a financing activity. We have also elected to continue to estimate the impact of forfeitures when determining the amount of compensation cost to be recognized each period rather than account for forfeitures as they occur. In October 2016, the FASB issued a new income tax standard that eliminates the exception for an intra-entity asset transfer other than inventory. Under the new standard, entities should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Any deferred tax asset that arises in the buyer's jurisdiction would also be recognized at the time of the transfer. We elected to early adopt this standard in the first quarter 2017. As a result of the adoption, in the first quarter of 2017, we recorded a $19 decrease in retained earnings, primarily resulting from the elimination of previously recorded prepaid tax assets. In January 2017, the FASB issued a new standard that clarifies the definition of a business and determines when an integrated set of assets and activities is not a business. This framework requires that if substantially all of the fair value of gross assets acquired or disposed of is concentrated in a single asset or group of similar identifiable assets, the assets would not represent a business. The standard is effective for interim and annual periods beginning after December 15, 2017 with early adoption permitted. We are currently assessing the impact of this standard on our financial condition and results of operations.

Inventories

3 Months Ended

Mar. 31, 2017

Inventory, Net [Abstract]

Inventories

Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of inventory on a standard cost basis, which approximates average costs.

The components of inventory are as follows:



	March 31,		December 31,
	2017		2016
Raw materials	$	22	$	17
Work-in-process	171		143
Finished goods	203		215
	$	396	$	375

Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

tangible Assets and Goodwill

The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:



		March 31, 2017							December 31, 2016
	Estimated Life (years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	6-8	$	29	$	(29	)	$	—	$	29	$	(29	)	$	—
Patents	7	11		(11		)	—		11		(11		)	—
Purchased technology	6-16	4,711		(519		)	4,192		4,711		(439		)	4,272
Acquired IPR&D	Indefinite	31		—			31		31		—			31
Total		$	4,782	$	(559	)	$	4,223	$	4,782	$	(479	)	$	4,303
Goodwill	Indefinite	$	5,040	$	(3	)	$	5,037	$	5,040	$	(3	)	$	5,037

Amortization expense was $80 for the three months ended March 31, 2017 and 2016. Assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is $240 for the nine months ending December 31, 2017, and $320 for each of the years ending December 31, 2018 through December 31, 2022.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt	3 Months Ended
Debt	Mar. 31, 2017
Debt [Abstract]
Debt	Debt On June 22, 2015, Alexion entered into a credit agreement (Credit Agreement) with a syndicate of banks, which provides for a $3,500 term loan facility and a $500 revolving credit facility maturing in five years. Borrowings under the term loan are payable in quarterly installments equal to 1.25% of the original loan amount, beginning December 31, 2015. Final repayment of the term loan and revolving credit loans are due on June 22, 2020. In addition to borrowings in which prior notice is required, the revolving credit facility includes a sublimit of $100 in the form of letters of credit and borrowings on same-day notice, referred to as swingline loans, of up to $25. Borrowings can be used for working capital requirements, acquisitions and other general corporate purposes. With the consent of the lenders and the administrative agent, and subject to satisfaction of certain conditions, we may increase the term loan facility and/or the revolving credit facility in an amount that does not cause our consolidated net leverage ratio to exceed the maximum allowable amount. In connection with entering into the Credit Agreement, we paid $45 in financing costs which are being amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended March 31, 2017 and 2016 was $2 and $3, respectively. We made principal payments of $44 during the three months ended March 31, 2017. As of March 31, 2017, we had $3,037 outstanding on the term loan. As of March 31, 2017, we had open letters of credit of $16, and our borrowing availability under the revolving facility was $484. The fair value of our long term debt, which is measured using Level 2 inputs, approximates book value.

Earnings Per Common Share

3 Months Ended

Mar. 31, 2017

Earnings Per Common Share [Abstract]

Earnings Per Common Share

Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.

The following table summarizes the calculation of basic and diluted EPS for the three months ended March 31, 2017 and 2016:



	Three months ended
	March 31,
	2017		2016
Net income used for basic and diluted calculation	$	170	$	92
Shares used in computing earnings per common share—basic	224		225
Weighted-average effect of dilutive securities:
Stock awards	2		2
Shares used in computing earnings per common share—diluted	226		227
Earnings per common share:
Basic	$	0.76	$	0.41
Diluted	$	0.75	$	0.41

We exclude from EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three months ended March 31, 2017 and 2016 were 6 and 4 shares of common stock, respectively, because their effect was anti-dilutive.

Marketable Securities

3 Months Ended

Mar. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities [Text Block]

Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale investments by type of security as of March 31, 2017 and December 31, 2016 were as follows:



	March 31, 2017
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Commercial paper	$	38	$	—	$	—		$	38
Corporate bonds	387		—		—			387
Municipal bonds	15		—		—			15
Other government-related obligations:
U.S.	7		—		—			7
Foreign	331		—		(1		)	330
Bank certificates of deposit	11		—		—			11
Total available-for-sale debt securities	789		—		(1		)	788
Equity securities	—		1		—			1
Total available-for-sale securities	789		1		(1		)	789



	December 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Commercial paper	$	114	$	—	$	—		$	114
Corporate bonds	124		—		(1		)	123
Municipal bonds	91		—		—			91
Other government-related obligations:
U.S.	28		—		—			28
Foreign	73		—		(1		)	72
Bank certificates of deposit	5		—		—			5
Total available-for-sale debt securities	$	435	$	—	$	(2	)	$	433
Equity securities	—		1		—			1
Total available-for-sale securities	435		1		(2		)	434

The aggregate fair value of available-for-sale securities in an unrealized loss position as of March 31, 2017 and December 31, 2016 was $485 and $265, respectively. These investments have been in a continuous unrealized loss position for less than 12 months. As of March 31, 2017, we believe that the cost basis of our available-for-sale investments is recoverable.

The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:



	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	57	$	120
Marketable securities	732		314
	$	789	$	434

The fair values of available-for-sale debt securities at March 31, 2017, by contractual maturity, are summarized as follows:



	March 31, 2017
Due in one year or less	$	405
Due after one year through three years	383
	$	788

As of March 31, 2017 and December 31, 2016, the fair value of our trading securities was $17 and $13, respectively.

We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our available-for-sale and trading securities were not material for the three months ended March 31, 2017 and 2016.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Derivative Instruments and Hedging Activities

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities [Abstract]

Derivative Instruments and Hedging Activities

We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on our outstanding term loan debt. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.

We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues. These hedges are designated as cash flow hedges upon contract inception. As of March 31, 2017, we had open foreign exchange forward contracts with notional amounts totaling $1,733 that qualified for hedge accounting.

To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread. The interest rate swap contracts executed as of March 31, 2017 are as follows:



Type of Interest Rate Swap	Notional Amount	Effective Date	Termination Date	Fixed Interest Rate
Floating to Fixed	$656	December 31, 2016	December 31, 2019	0.98%
Floating to Fixed	$300	January 31, 2017	December 31, 2018	1.29%
Floating to Fixed	$300	January 02, 2019	December 31, 2019	2.08%

Subsequent to March 31, 2017, we entered into two additional interest rate swap agreements. The first agreement has a notional amount of $200 that is effective through December 31, 2019 and converts the floating rate on a portion of our term loan to a fixed rate of 1.62%, plus a borrowing spread. The second agreement has a notional amount of $200 that is effective through December 31, 2018 and converts the floating rate on a portion of our term loan to a fixed rate of 1.40%, plus a borrowing spread.

The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three months ended March 31, 2017 and 2016, were as follows:



	Three months ended
	March 31,
Foreign Exchange Contracts:	2017			2016
Gain (loss) recognized in AOCI, net of tax	$	(16	)	$	(49	)
Gain reclassified from AOCI to net product sales (effective portion), net of tax	$	13		$	15
Interest Rate Contracts:
Gain recognized in AOCI, net of tax	$	1		$	—
Gain reclassified from AOCI to interest expense, net of tax	$	—		$	—

Assuming no change in foreign exchange rates or LIBOR-based interest rates from market rates at March 31, 2017, $54 of gains recognized in AOCI will be reclassified to revenue over the next 12 months. The amount of gains recognized in AOCI that will be reclassified to interest expense over the next 12 months is $2.

We enter into foreign exchange forward contracts, with durations of approximately 90 days, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of March 31, 2017, the notional amount of foreign exchange contracts where hedge accounting is not applied was $634.

We recognized a loss of $9 and $13, in other income and expense, for the three months ended March 31, 2017 and 2016, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.

The following tables summarize the fair value of outstanding derivatives as of March 31, 2017 and December 31, 2016:



	March 31, 2017
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	61	Other current liabilities	$	7
Foreign exchange forward contracts	Other assets	43		Other liabilities	9
Interest rate contracts	Prepaid expenses and other current assets	2		Other current liabilities	—
Interest rate contracts	Other assets	10		Other liabilities	—
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	4		Other current liabilities	7
Total fair value of derivative instruments		$	120		$	23



	December 31, 2016
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	80	Other current liabilities	$	2
Foreign exchange forward contracts	Other assets	59		Other liabilities	4
Interest rate contracts	Prepaid expenses and other current assets	—		Other current liabilities	—
Interest rate contracts	Other assets	10		Other liabilities	—
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	17			10
Total fair value of derivative instruments		$	166		$	16

Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:



	March 31, 2017
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	120		$	—	$	120		$	(23	)	$	—	$	97
Derivative liabilities	(23		)	—		(23		)	23			—		—



	December 31, 2016
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	166		$	—	$	166		$	(16	)	$	—	$	150
Derivative liabilities	(16		)	—		(16		)	16			—		—

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Other Investments	3 Months Ended
Other Investments	Mar. 31, 2017
Investments, All Other Investments [Abstract]
Other investments	Other Investments Other investments include our investment of $38 in the preferred stock of Moderna Therapeutics, Inc. Our investment is recorded at cost within other assets in our condensed consolidated balance sheets. The carrying value of this investment was not impaired as of March 31, 2017.

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Mar. 31, 2017
Equity [Abstract]
Stockholders' Equity	In November 2012, our Board of Directors authorized a share repurchase program. The repurchase program does not have an expiration date, and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at the Company's discretion. In February 2017, our Board of Directors increased the authorization to acquire shares with an aggregate value of up to $1,000 for future purchases under the repurchase program, which superseded all prior repurchase programs. During the three months ended March 31, 2017 and 2016, we repurchased 1 and 2 shares of our common stock under the program at a cost of $68 and $297, respectively. Subsequent to March 31, 2017, we repurchased common stock under our repurchase program at a cost of $32. As of April 27, 2017, there was a total of $900 remaining for repurchases under the repurchase program.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Other Comprehensive Income and Accumulated Other Comprehensive Income

3 Months Ended

Mar. 31, 2017

Accumulated Other Comprehensive Income [Abstract]

Other Comprehensive Income and Accumulated Other Comprehensive Income

The following tables summarize the changes in AOCI, by component, for the three months ended March 31, 2017 and 2016:



	Defined Benefit Pension Plans		Unrealized Gains (Losses) from Marketable Securities		Unrealized Gains (Losses) from Hedging Activities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2016	(7	)	(1	)	92		(24	)	60
Other comprehensive income before reclassifications	—		—		(15	)	—		(15	)
Amounts reclassified from other comprehensive income	—		1		(13	)	3		(9	)
Net other comprehensive income (loss)	—		1		(28	)	3		(24	)
Balances, March 31, 2017	(7	)	—		64		(21	)	36



	Defined Benefit Pension Plan		Unrealized Gains (Losses) from Marketable Securities		Unrealized Gains (Losses) From Hedging Activities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2015	(10	)	(1	)	93		(20	)	62
Other comprehensive income before reclassifications	2		1		(49	)	2		(44	)
Amounts reclassified from other comprehensive income	—		1		(15	)	—		(14	)
Net other comprehensive income (loss)	2		2		(64	)	2		(58	)
Balances, March 31, 2016	(8	)	1		29		(18	)	4

The table below provides details regarding significant reclassifications from AOCI during the three months ended March 31, 2017 and 2016:



Details about Accumulated Other Comprehensive Income Components	Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended March 31,						Affected Line Item in the Condensed Consolidated Statements of Operations
	2017			2016
Unrealized Gains (Losses) from Hedging Activity
Effective portion of foreign exchange contracts	$	20		$	23		Net product sales
Effective portion of interest rate swap contracts	(1		)	—			Interest expense
	19			23
	(6		)	(8		)	Income tax expense
	$	13		$	15

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Fair Value Measurement

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurement

Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.



		Fair Value Measurement at March 31, 2017
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	32	$	—	$	32	$	—
Cash equivalents	Commercial paper	$	17	$	—	$	17	$	—
Cash equivalents	Corporate bonds	$	12	$	—	$	12	$	—
Cash equivalents	Municipal bonds	$	14	$	—	$	14	$	—
Cash equivalents	Other government-related obligations	$	14	$	—	$	14	$	—
Marketable securities	Mutual funds	$	17	$	17	$	—	$	—
Marketable securities	Commercial paper	$	21	$	—	$	21	$	—
Marketable securities	Corporate bonds	$	375	$	—	$	375	$	—
Marketable securities	Municipal bonds	$	1	$	—	$	1	$	—
Marketable securities	Other government-related obligations	$	323	$	—	$	323	$	—
Marketable securities	Bank certificates of deposit	$	11	$	—	$	11	$	—
Marketable securities	Equity securities	$	1	$	1	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	65	$	—	$	65	$	—
Other assets	Foreign exchange forward contracts	$	43	$	—	$	43	$	—
Other current liabilities	Foreign exchange forward contracts	$	14	$	—	$	14	$	—
Other liabilities	Foreign exchange forward contracts	$	9	$	—	$	9	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	2	$	—	$	2	$	—
Other assets	Interest rate contracts	$	10	$	—	$	10	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	25	$	—	$	—	$	25
Contingent consideration	Acquisition-related contingent consideration	$	132	$	—	$	—	$	132



		Fair Value Measurement at December 31, 2016
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	266	$	—	$	266	$	—
Cash equivalents	Commercial paper	$	70	$	—	$	70	$	—
Cash equivalents	Corporate bonds	$	10	$	—	$	10	$	—
Cash equivalents	Municipal bonds	$	40	$	—	$	40	$	—
Marketable securities	Mutual funds	$	13	$	13	$	—	$	—
Marketable securities	Commercial paper	$	44	$	—	$	44	$	—
Marketable securities	Corporate bonds	$	113	$	—	$	113	$	—
Marketable securities	Municipal bonds	$	51	$	—	$	51	$	—
Marketable securities	Other government-related obligations	$	100	$	—	$	100	$	—
Marketable securities	Bank certificates of deposit	$	5	$	—	$	5	$	—
Marketable securities	Equity securities	$	1	$	1	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	97	$	—	$	97	$	—
Other assets	Foreign exchange forward contracts	$	59	$	—	$	59	$	—
Other current liabilities	Foreign exchange forward contracts	$	12	$	—	$	12	$	—
Other liabilities	Foreign exchange forward contracts	$	4	$	—	$	4	$	—
Other assets	Interest rate contracts	$	10	$	—	$	10	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	24	$	—	$	—	$	24
Contingent consideration	Acquisition-related contingent consideration	$	129	$	—	$	—	$	129

There were no securities transferred between Level 1, 2 and 3 during the three months ended March 31, 2017.

Valuation Techniques

We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.

Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy consist of institutional money market funds, commercial paper, municipal bonds, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.

Our derivative assets and liabilities include foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.

Contingent consideration liabilities related to acquisitions are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.

As of March 31, 2017, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.

Contingent Consideration

In connection with prior acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations on the acquisition date using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt of 4.7% for developmental milestones and a weighted average cost of capital ranging from 10% to 21% for sales-based milestones.

Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.

Estimated future contingent milestone payments related to prior business combinations range from zero if no milestone events are achieved, to a maximum of $766 if all development, regulatory and sales-based milestones are reached. As of March 31, 2017, the fair value of acquisition-related contingent consideration was $157. The following table represents a roll-forward of our acquisition-related contingent consideration:



	Three months ended March 31, 2017
Balance as of December 31, 2016	$	(153	)
Changes in fair value	(4		)
Balance as of March 31, 2017	$	(157	)

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

3 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

The following table provides a comparative summary of our income tax expense and effective income tax rate for the three months ended March 31, 2017 and 2016:



	Three months ended
	March 31,
	2017			2016
Income tax expense	$	24		$	51
Effective income tax rate	12.4		%	35.8		%

The income tax expense for the three months ended March 31, 2017 and 2016 is attributable to the U.S. federal, state and foreign income taxes on our profitable operations. The decrease in the effective tax rate for the three months ended March 31, 2017 as compared to the same period in the prior year is primarily attributable to the deferred tax cost associated with the distribution of earnings from our captive foreign partnership in 2016. The absence of this non-cash deferred tax cost decreased the effective tax rate by approximately 19%.

The Internal Revenue Service (IRS) has commenced an examination of our U.S. income tax returns for 2013 and 2014. We anticipate this audit will conclude within the next twelve months. As of April 27, 2017, we had not received a Notice of Proposed Adjustment from the IRS.

We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.

Defined Benefit Plans	3 Months Ended
Defined Benefit Plans	Mar. 31, 2017
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Defined Benefit Plans We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments. The total net periodic benefit cost for each of the three months ended March 31, 2017 and 2016 was $2, primarily related to service costs.

Facility Lease Obligations	3 Months Ended
Facility Lease Obligations	Mar. 31, 2017
Leases [Abstract]
Leases	Facility Lease Obligations New Haven Facility Lease Obligation In November 2012, we entered into a lease agreement for office and laboratory space to be constructed in New Haven, Connecticut. The term of the lease commenced in 2015 and will expire in 2030, with a renewal option of ten years. Although we do not legally own the premises, we are deemed to be the owner of the building due to the substantial improvements directly funded by us during the construction period based on applicable accounting guidance for build-to-suit leases. Accordingly, the landlord's costs of constructing the facility during construction period are required to be capitalized, as a non-cash transaction, offset by a corresponding facility lease obligation in our consolidated balance sheet. Construction of the facility was completed and the building was placed into service in the first quarter 2016. As of March 31, 2017 and December 31, 2016, our total facility lease obligation was $135 and $136, respectively, recorded within other current liabilities and facility lease obligation on our condensed consolidated balance sheets. Lonza Facility Lease Obligation During the third quarter 2015, we entered into a new agreement with Lonza Group AG and its affiliates (Lonza) whereby Lonza will construct a new manufacturing facility dedicated to Alexion at one of its existing facilities. The agreement requires us to make certain payments during the construction of the new manufacturing facility and annual payments for ten years thereafter. As a result of our contractual right to full capacity of the new manufacturing facility, a portion of the payments under the agreement are considered to be lease payments and a portion as payment for the supply of inventory. Although we will not legally own the premises, we are deemed to be the owner of the manufacturing facility during the construction period based on applicable accounting guidance for build-to-suit leases due to our involvement during the construction period. As of March 31, 2017 and December 31, 2016, we recorded a construction-in-process asset of $158 and $118, respectively, and an offsetting facility lease obligation of $142 and $107, respectively, associated with the manufacturing facility. Payments to Lonza under the agreement are allocated to the purchases of inventory and the repayment of the facility lease obligation on a relative fair value basis. In 2017, we incurred $29 of payments to Lonza under this agreement, of which $4 was applied against the outstanding facility lease obligation and $25 was recognized as a prepayment of inventory. See Note 16 for minimum fixed payments due under Lonza agreements.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments License Agreements We have entered into a number of license agreements in order to advance and obtain technologies and services related to our business. License agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any. In March 2017, we entered into a license agreement with Arbutus Biopharma Corporation (Arbutus) for exclusive worldwide rights to Arbutus’ proprietary lipid nanoparticle technology for use in a single target. Due to the early stage of the assets we are licensing in connection with the collaboration, we recorded expense for the upfront payment of approximately $8 during the first quarter 2017. In addition, we could be required to make payments of up to $75 if certain development, regulatory, and commercial milestones are met over time, as well as royalties on commercial sales. Manufacturing Agreements We have various manufacturing development and license agreements to support our clinical and commercial product needs. We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of Soliris and Strensiq. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,126. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of Soliris manufactured at Alexion Rhode Island Manufacturing Facility (ARIMF) and a payment with respect to sales of Soliris manufactured at Lonza facilities. In addition to Lonza, we have non-cancellable commitments of $27 with other third party manufacturers. Contingent Liabilities We are currently involved in various claims, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. We have in the past received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the development, manufacture or sale of our products. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results. In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the SEC requesting information related to our grant-making activities and compliance with the FCPA in various countries. In addition, in October 2015, we received a request from the DOJ for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of Soliris and related securities disclosures. Alexion is cooperating with these investigations. The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws. At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of any such loss or range of loss, or the cost of the ongoing investigation. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. Alexion is committed to strengthening its compliance program and has initiated a comprehensive company-wide transformation plan to enhance and remediate its business processes, structures, controls, training, talent and systems across Alexion’s global operations. For information concerning the risks associated with the investigation, see our Risk Factor - "If we fail to comply with laws or regulations, we may be subject to investigations and civil or criminal penalties and our business could be adversely affected." In the fourth quarter 2016, several securities class action lawsuits were filed against the Company and its former officers in federal district court alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78j(b), and Rule 10b-5, promulgated thereunder, alleging that defendants made misstatements and/or omissions concerning the Company’s sales of Soliris. On April 12, 2017 the U.S. District Court for the District of Connecticut (the Court) awarded lead plaintiff status to Erste-Sparinvest KapitalanLagegesellschaft mbH (Erste) and the Public Employee Retirement System of Idaho (PERSI). Erste and PERSI filed its shareholder putative class action with the Court on December 29, 2016, alleging that defendants made misrepresentations and omissions about Soliris between February 10, 2014 and December 9, 2016. The litigation is in the early stages, and defendants have not yet responded to the complaint. Given the early stages of this litigation, management does not currently believe that a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated. In December 2016, we received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting documents relating generally to our support of 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion, Alexion’s provision of free drug to Medicare patients, and Alexion compliance policies and training materials concerning the anti-kickback statute or payments to any 501(c)(3) organization that provides financial assistance to Medicare patients. Other companies have disclosed similar inquiries. We are cooperating with this inquiry. In March 2013, we received a Warning Letter (Warning Letter) from the U.S. Food and Drug Administration (FDA) regarding compliance with current Good Manufacturing Practices (cGMP) at ARIMF. The Warning Letter followed receipt of a Form 483 Inspectional Observations by the FDA in connection with an FDA inspection that concluded in August 2012. The observations relate to commercial and clinical manufacture of Soliris at ARIMF. We responded to the Warning Letter in a letter to the FDA dated in April 2013. As previously disclosed, the FDA issued Form 483s in August 2014 and August 2015 related to observations at ARIMF and the inspectional observations from the August 2014 and 2015 Forms 483s have since been closed out by the FDA. During July 2016, the FDA completed a routine inspection at ARIMF and have since confirmed receipt of our responses to the inspectional observations included in the Form 483 received during that inspection. The observations are inspectional and do not represent a final FDA determination of compliance. We continue to manufacture products, including Soliris, in this facility. While the resolution of the issues raised in the Warning Letter is difficult to predict, we do not currently believe a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.

Restructuring

3 Months Ended

Mar. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring

In the first quarter 2017, we initiated a company-wide restructuring designed to help position the Company for sustainable, long-term growth that we believe will further allow us to fulfill our mission of serving patients and families with rare diseases. For the three months ended March 31, 2017 we recorded $24 of restructuring expenses primarily related to employee separation costs. We currently estimate incurring approximately $5 to $10 of additional restructuring related expenses in 2017. We expect to pay all accrued amounts related to this restructuring within twelve months.

The following table presents a reconciliation of the restructuring reserve recorded within accrued expenses on the Company's condensed consolidated balance sheet for the three months ended March 31, 2017:



	Employee Separation Costs		Contract Termination Costs		Other Costs			Total
Liability, beginning of period	$	—	$	—	$	—		$	—
Restructuring expenses	21		—		3			24
Cash settlements	—		—		—			—
Adjustments to previous estimates	—		—		—			—
Asset impairments	—		—		(3		)	(3		)
Liability, end of period	$	21	$	—	$	—		$	21

The restructuring reserve of $21 is recorded in accrued expenses on the Company's condensed consolidated balance sheet as of March 31, 2017.

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventory, Net [Abstract]

Schedule of Inventory, Current

The components of inventory are as follows:



	March 31,		December 31,
	2017		2016
Raw materials	$	22	$	17
Work-in-process	171		143
Finished goods	203		215
	$	396	$	375

Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

e following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:



		March 31, 2017							December 31, 2016
	Estimated Life (years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	6-8	$	29	$	(29	)	$	—	$	29	$	(29	)	$	—
Patents	7	11		(11		)	—		11		(11		)	—
Purchased technology	6-16	4,711		(519		)	4,192		4,711		(439		)	4,272
Acquired IPR&D	Indefinite	31		—			31		31		—			31
Total		$	4,782	$	(559	)	$	4,223	$	4,782	$	(479	)	$	4,303
Goodwill	Indefinite	$	5,040	$	(3	)	$	5,037	$	5,040	$	(3	)	$	5,037

Earnings Per Common Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Common Share [Abstract]

Schedule Of Basic And Diluted Earnings Per Share

The following table summarizes the calculation of basic and diluted EPS for the three months ended March 31, 2017 and 2016:



	Three months ended
	March 31,
	2017		2016
Net income used for basic and diluted calculation	$	170	$	92
Shares used in computing earnings per common share—basic	224		225
Weighted-average effect of dilutive securities:
Stock awards	2		2
Shares used in computing earnings per common share—diluted	226		227
Earnings per common share:
Basic	$	0.76	$	0.41
Diluted	$	0.75	$	0.41

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]



	March 31, 2017
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Commercial paper	$	38	$	—	$	—		$	38
Corporate bonds	387		—		—			387
Municipal bonds	15		—		—			15
Other government-related obligations:
U.S.	7		—		—			7
Foreign	331		—		(1		)	330
Bank certificates of deposit	11		—		—			11
Total available-for-sale debt securities	789		—		(1		)	788
Equity securities	—		1		—			1
Total available-for-sale securities	789		1		(1		)	789



	December 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Commercial paper	$	114	$	—	$	—		$	114
Corporate bonds	124		—		(1		)	123
Municipal bonds	91		—		—			91
Other government-related obligations:
U.S.	28		—		—			28
Foreign	73		—		(1		)	72
Bank certificates of deposit	5		—		—			5
Total available-for-sale debt securities	$	435	$	—	$	(2	)	$	433
Equity securities	—		1		—			1
Total available-for-sale securities	435		1		(2		)	434

Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]

The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:



	March 31, 2017		December 31, 2016
Cash and cash equivalents	$	57	$	120
Marketable securities	732		314
	$	789	$	434

Investments Classified by Contractual Maturity Date [Table Text Block]

The fair values of available-for-sale debt securities at March 31, 2017, by contractual maturity, are summarized as follows:



	March 31, 2017
Due in one year or less	$	405
Due after one year through three years	383
	$	788

Derivative Instruments and Hedging Activities (Tables)

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities [Abstract]

Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts



	Three months ended
	March 31,
Foreign Exchange Contracts:	2017			2016
Gain (loss) recognized in AOCI, net of tax	$	(16	)	$	(49	)
Gain reclassified from AOCI to net product sales (effective portion), net of tax	$	13		$	15
Interest Rate Contracts:
Gain recognized in AOCI, net of tax	$	1		$	—
Gain reclassified from AOCI to interest expense, net of tax	$	—		$	—

Schedule of Fair Value of Outstanding Derivatives

The following tables summarize the fair value of outstanding derivatives as of March 31, 2017 and December 31, 2016:



	March 31, 2017
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	61	Other current liabilities	$	7
Foreign exchange forward contracts	Other assets	43		Other liabilities	9
Interest rate contracts	Prepaid expenses and other current assets	2		Other current liabilities	—
Interest rate contracts	Other assets	10		Other liabilities	—
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	4		Other current liabilities	7
Total fair value of derivative instruments		$	120		$	23



	December 31, 2016
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	80	Other current liabilities	$	2
Foreign exchange forward contracts	Other assets	59		Other liabilities	4
Interest rate contracts	Prepaid expenses and other current assets	—		Other current liabilities	—
Interest rate contracts	Other assets	10		Other liabilities	—
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	17			10
Total fair value of derivative instruments		$	166		$	16

Offsetting Assets and Liabilities [Table Text Block]

The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:



	March 31, 2017
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	120		$	—	$	120		$	(23	)	$	—	$	97
Derivative liabilities	(23		)	—		(23		)	23			—		—



	December 31, 2016
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	166		$	—	$	166		$	(16	)	$	—	$	150
Derivative liabilities	(16		)	—		(16		)	16			—		—

Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2017

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income

The following tables summarize the changes in AOCI, by component, for the three months ended March 31, 2017 and 2016:



	Defined Benefit Pension Plans		Unrealized Gains (Losses) from Marketable Securities		Unrealized Gains (Losses) from Hedging Activities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2016	(7	)	(1	)	92		(24	)	60
Other comprehensive income before reclassifications	—		—		(15	)	—		(15	)
Amounts reclassified from other comprehensive income	—		1		(13	)	3		(9	)
Net other comprehensive income (loss)	—		1		(28	)	3		(24	)
Balances, March 31, 2017	(7	)	—		64		(21	)	36



	Defined Benefit Pension Plan		Unrealized Gains (Losses) from Marketable Securities		Unrealized Gains (Losses) From Hedging Activities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2015	(10	)	(1	)	93		(20	)	62
Other comprehensive income before reclassifications	2		1		(49	)	2		(44	)
Amounts reclassified from other comprehensive income	—		1		(15	)	—		(14	)
Net other comprehensive income (loss)	2		2		(64	)	2		(58	)
Balances, March 31, 2016	(8	)	1		29		(18	)	4

Reclassification out of AOCI

The table below provides details regarding significant reclassifications from AOCI during the three months ended March 31, 2017 and 2016:



Details about Accumulated Other Comprehensive Income Components	Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended March 31,						Affected Line Item in the Condensed Consolidated Statements of Operations
	2017			2016
Unrealized Gains (Losses) from Hedging Activity
Effective portion of foreign exchange contracts	$	20		$	23		Net product sales
Effective portion of interest rate swap contracts	(1		)	—			Interest expense
	19			23
	(6		)	(8		)	Income tax expense
	$	13		$	15

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule Of Assets And Liabilites Measured At Fair Value



		Fair Value Measurement at March 31, 2017
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	32	$	—	$	32	$	—
Cash equivalents	Commercial paper	$	17	$	—	$	17	$	—
Cash equivalents	Corporate bonds	$	12	$	—	$	12	$	—
Cash equivalents	Municipal bonds	$	14	$	—	$	14	$	—
Cash equivalents	Other government-related obligations	$	14	$	—	$	14	$	—
Marketable securities	Mutual funds	$	17	$	17	$	—	$	—
Marketable securities	Commercial paper	$	21	$	—	$	21	$	—
Marketable securities	Corporate bonds	$	375	$	—	$	375	$	—
Marketable securities	Municipal bonds	$	1	$	—	$	1	$	—
Marketable securities	Other government-related obligations	$	323	$	—	$	323	$	—
Marketable securities	Bank certificates of deposit	$	11	$	—	$	11	$	—
Marketable securities	Equity securities	$	1	$	1	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	65	$	—	$	65	$	—
Other assets	Foreign exchange forward contracts	$	43	$	—	$	43	$	—
Other current liabilities	Foreign exchange forward contracts	$	14	$	—	$	14	$	—
Other liabilities	Foreign exchange forward contracts	$	9	$	—	$	9	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	2	$	—	$	2	$	—
Other assets	Interest rate contracts	$	10	$	—	$	10	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	25	$	—	$	—	$	25
Contingent consideration	Acquisition-related contingent consideration	$	132	$	—	$	—	$	132



		Fair Value Measurement at December 31, 2016
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	266	$	—	$	266	$	—
Cash equivalents	Commercial paper	$	70	$	—	$	70	$	—
Cash equivalents	Corporate bonds	$	10	$	—	$	10	$	—
Cash equivalents	Municipal bonds	$	40	$	—	$	40	$	—
Marketable securities	Mutual funds	$	13	$	13	$	—	$	—
Marketable securities	Commercial paper	$	44	$	—	$	44	$	—
Marketable securities	Corporate bonds	$	113	$	—	$	113	$	—
Marketable securities	Municipal bonds	$	51	$	—	$	51	$	—
Marketable securities	Other government-related obligations	$	100	$	—	$	100	$	—
Marketable securities	Bank certificates of deposit	$	5	$	—	$	5	$	—
Marketable securities	Equity securities	$	1	$	1	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	97	$	—	$	97	$	—
Other assets	Foreign exchange forward contracts	$	59	$	—	$	59	$	—
Other current liabilities	Foreign exchange forward contracts	$	12	$	—	$	12	$	—
Other liabilities	Foreign exchange forward contracts	$	4	$	—	$	4	$	—
Other assets	Interest rate contracts	$	10	$	—	$	10	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	24	$	—	$	—	$	24
Contingent consideration	Acquisition-related contingent consideration	$	129	$	—	$	—	$	129

Schedule Of Acquisition-Related Contingent Consideration

The following table represents a roll-forward of our acquisition-related contingent consideration:



	Three months ended March 31, 2017
Balance as of December 31, 2016	$	(153	)
Changes in fair value	(4		)
Balance as of March 31, 2017	$	(157	)

Restructuring (Tables)

3 Months Ended

Mar. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs



	Employee Separation Costs		Contract Termination Costs		Other Costs			Total
Liability, beginning of period	$	—	$	—	$	—		$	—
Restructuring expenses	21		—		3			24
Cash settlements	—		—		—			—
Adjustments to previous estimates	—		—		—			—
Asset impairments	—		—		(3		)	(3		)
Liability, end of period	$	21	$	—	$	—		$	21

Basis of Presentation and Principles Of Consolidation - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease in retained earnings from adoption of new accounting principle	$ (19)
New Accounting Pronouncement, Early Adoption, Effect \| Long-term Debt, Current Maturities
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs
New Accounting Pronouncement, Early Adoption, Effect \| Long-term Debt, Excluding Current Maturities
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs

Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory, Raw Materials	$ 22	$ 17
Inventory, Work in Process	171	143
Inventory, Finished Goods	203	215
Inventory, Net	$ 396	$ 375

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Cost	$ 4,782	$ 4,782
Intangible Assets, Accumulated Amortization	(559)	(479)
Intangible Assets, Net	4,223	4,303
Goodwill, Gross	5,040	5,040
Goodwill, Accumulated Amortization	(3)	(3)
Goodwill, Net	5,037	5,037
Licenses
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	29	29
Finite-Lived Intangible Assets, Accumulated Amortization	(29)	(29)
Finite-Lived Intangible Assets, Net	$ 0	0
Licenses \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Life (years)	6 years
Licenses \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Life (years)	8 years
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated Life (years)	7 years
Finite-Lived Intangible Assets, Gross	$ 11	11
Finite-Lived Intangible Assets, Accumulated Amortization	(11)	(11)
Finite-Lived Intangible Assets, Net	0	0
Purchased technology
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,711	4,711
Finite-Lived Intangible Assets, Accumulated Amortization	(519)	(439)
Finite-Lived Intangible Assets, Net	$ 4,192	4,272
Purchased technology \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Life (years)	6 years
Purchased technology \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Life (years)	16 years
Acquired IPR&D
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Asset, Cost	$ 31	31
Indefinite-Lived Intangible Assets, Accumulated Amortization	$ 0	$ 0

Intangible Assets and Goodwill (Schedule of Goodwill) (Details) $ in Millions	Mar. 31, 2017 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 5,037
Goodwill, ending balance	$ 5,037

Intangible Assets and Goodwill (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 80	$ 80
Finite-lived intangible assets, 2017	240
Finite-lived intangible assets, 2018	320
Finite-lived intangible assets, 2019	320
Finite-lived intangible assets, 2020	320
Finite-lived intangible assets, 2021	320
Finite-lived intangible assets, 2022	$ 320

Debt (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
Debt (Details) - USD ($) $ in Millions	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015	Jun. 22, 2015
Debt Instrument [Line Items]
Repayments of Debt	$ 44
Amortization of Financing Costs	2	$ 3
Credit Agreement [Member]
Debt Instrument [Line Items]
Payments of Financing Costs			$ 45
Senior Secured Term Loan [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount				$ 3,500
Debt Instrument, Quarterly Payment, Percentage of Total Borrowings				1.25%
Outstanding debt	3,037
Line of Credit [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 500
Letters of credit, amount outstanding	16
Line of credit facility, borrowing availability	$ 484
Letter of Credit [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Sublimit for letter of credit for working capital requirements and other general corporate purposes				100
Bridge Loan [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Sublimit for letter of credit for working capital requirements and other general corporate purposes				$ 25

Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Common Share [Abstract]
Net income used for basic and diluted calculation	$ 170	$ 92
Shares used in computing earnings per common share—basic	224	225
Stock awards	2	2
Shares used in computing earnings per common share-diluted	226	227
Earnings Per Share, Basic	$ 0.76	$ 0.41
Earnings Per Share, Diluted	$ 0.75	$ 0.41

Earnings Per Common Share (Dilutive Shares Excluded From Calculatin Of Earnings Per Share) (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Common Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6	4

Marketable Securities (Summary of Available-for-Sale Securities Held) (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	$ 789	$ 435
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(1)	(2)
Available-for-sale Securities, Debt Securities	788	433
Available-for-sale Equity Securities, Amortized Cost Basis	0	0
Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax	1	1
Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Equity Securities	1	1
Available-for-sale Securities, Amortized Cost Basis	789	435
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	1	1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(1)	(2)
Available-for-sale Securities	789	434
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	38	114
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Debt Securities	38	114
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	387	124
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	0	(1)
Available-for-sale Securities, Debt Securities	387	123
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	15	91
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Debt Securities	15	91
US Government Agencies Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	7	28
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Debt Securities	7	28
Foreign Government Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	331	73
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(1)	(1)
Available-for-sale Securities, Debt Securities	330	72
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	11	5
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Debt Securities	$ 11	$ 5

Marketable Securities Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 485	$ 265
Trading Securities	$ 17	$ 13

Marketable Securities (Available-for-Sale Securities by Classification in Balance Sheet) (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Debt Securities	$ 788	$ 433
Available-for-sale Securities	789	434
Cash and Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Debt Securities	57	120
Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Debt Securities	$ 732	$ 314

Marketable Securities (Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value	$ 405
Available-for-sale Securities, Debt Maturities, Year Two Through Three, Fair Value	383
Available-for-sale Securities, Debt Securities	$ 788	$ 433

Derivative Instruments and Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Foreign Exchange Forward Contracts Term	60 months
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Foreign Exchange Forward Contracts Term	90 days
Gain (loss) in other income and expense	$ (9)	$ (13)
Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount of Foreign Currency Derivatives	1,733
Foreign Exchange Forward [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Fair Value, Net Asset (Liability)
Notional Amount of Foreign Currency Derivatives	634
Foreign Exchange Contract [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Amount of gain (loss) to be reclassified from AOCI	54
Interest Rate Contract [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Amount of gain (loss) to be reclassified from AOCI	$ 2

Derivative Instruments and Hedging Activities (Schedule of Interest Rate Swap Contracts) (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Apr. 27, 2017	Mar. 31, 2017
Interest Rate Swap One [Member]
Derivative [Line Items]
Derivative, notional amount		$ 656
Derivative, fixed interest rate		0.98%
Interest Rate Swap Two [Member]
Derivative [Line Items]
Derivative, notional amount		$ 300
Derivative, fixed interest rate		1.29%
Interest Rate Swap Three [Member]
Derivative [Line Items]
Derivative, notional amount		$ 300
Derivative, fixed interest rate		2.08%
Subsequent Event [Member] \| Interest Rate Swap Four [Member]
Derivative [Line Items]
Derivative, notional amount	$ 200
Derivative, fixed interest rate	1.62%
Subsequent Event [Member] \| Interest Rate Swap Five [Member]
Derivative [Line Items]
Derivative, notional amount	$ 200
Derivative, fixed interest rate	1.40%

Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in AOCI, net of tax	$ (16)	$ (49)
Gain reclassified from AOCI to net product sales (effective portion), net of tax	13	15
Interest Rate Contract [Member] \| Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in AOCI, net of tax	1	0
Interest Rate Contract [Member] \| Interest Expense [Member] \| Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain reclassified from AOCI to net product sales (effective portion), net of tax	$ 0	$ 0

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Interest Rate Contract [Member] \| Prepaid expenses and other current assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 2	$ 0
Interest Rate Contract [Member] \| Other assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	10	10
Interest Rate Contract [Member] \| Other current liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0	0
Interest Rate Contract [Member] \| Other liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0	0
Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	120	166
Liability Derivatives, Fair Value	23	16
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	61	80
Foreign Exchange Forward [Member] \| Other assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	43	59
Foreign Exchange Forward [Member] \| Other current liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	7	2
Foreign Exchange Forward [Member] \| Other liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	9	4
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	4	17
Foreign Exchange Forward [Member] \| Other current liabilities \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 7	$ 10

Derivative Instruments and Hedging Activities (Schedule of Offsetting Assets and LIabilities) (Details) - Foreign Exchange Forward [Member] - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Offsetting Assets and Liabilities [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 120	$ 166
Derivative Asset, Fair Value, Gross Liability	0	0
Derivative Asset, Fair Value, Amount Not Offset Against Collateral	120	166
Derivative, Collateral, Obligation to Return Securities	(23)	(16)
Derivative, Collateral, Obligation to Return Cash	0	0
Derivative Asset, Fair Value, Amount Offset Against Collateral	97	150
Derivative Liability, Fair Value, Gross Liability	(23)	(16)
Derivative Liability, Fair Value, Gross Asset	0	0
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	23	16
Derivative, Collateral, Right to Reclaim Securities	23	16
Derivative, Collateral, Right to Reclaim Cash	0	0
Derivative Liability, Fair Value, Amount Offset Against Collateral	$ 0	$ 0

Other Investments (Details) $ in Millions	3 Months Ended
Other Investments (Details) $ in Millions	Mar. 31, 2017 USD ($)
Moderna LLC [Member]
Investment [Line Items]
Investment owned, at cost	$ 38

Stockholders' Equity (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Apr. 27, 2017	Mar. 31, 2017	Mar. 31, 2016	Feb. 28, 2017
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired		1	2
Treasury Stock, Value, Acquired, Cost Method		$ 68	$ 297
Subsequent Event [Member]
Class of Stock [Line Items]
Treasury Stock, Value, Acquired, Cost Method	$ 32
Common Stock [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount				$ 1,000
Total remaining amount for repurchases under program		$ 932
Common Stock [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Total remaining amount for repurchases under program	$ 900

Other Comprehensive Income and Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 60	$ 62
Other comprehensive income before reclassifications	(15)	(44)
Amounts reclassified from other comprehensive income	(9)	(14)
Net other comprehensive income (loss)	(24)	(58)
Ending balance	36	4
Defined Benefit Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(7)	(10)
Other comprehensive income before reclassifications	0	2
Amounts reclassified from other comprehensive income	0	0
Net other comprehensive income (loss)	0	2
Ending balance	(7)	(8)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(1)	(1)
Other comprehensive income before reclassifications	0	1
Amounts reclassified from other comprehensive income	1	1
Net other comprehensive income (loss)	1	2
Ending balance	0	1
Net Unrealized Gain (Loss) From Hedging Activities [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	92	93
Other comprehensive income before reclassifications	(15)	(49)
Amounts reclassified from other comprehensive income	(13)	(15)
Net other comprehensive income (loss)	(28)	(64)
Ending balance	64	29
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(24)	(20)
Other comprehensive income before reclassifications	0	2
Amounts reclassified from other comprehensive income	3	0
Net other comprehensive income (loss)	3	2
Ending balance	$ (21)	$ (18)

Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net product sales	$ 869	$ 700
Interest Expense	(24)	(24)
Investment income	4	1
Income before income taxes	194	143
Income tax expense	(24)	(51)
Net income	170	92
Reclassification out of Accumulated Other Comprehensive Income [Member] \| Net Unrealized Gain (Loss) From Hedging Activities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	19	23
Income tax expense	(6)	(8)
Net income	13	15
Foreign Exchange Contract [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Net Unrealized Gain (Loss) From Hedging Activities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net product sales	20	23
Interest Rate Swap [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Net Unrealized Gain (Loss) From Hedging Activities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest Expense	$ (1)	$ 0

Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	$ 0
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	766
Contingent consideration	132	$ 129
Acquisition Related Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration	$ 157
Acquisition Related Contingent Consideration [Member] \| Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cost of debt	4.70%
Acquisition-Related Contingent Consideration [Roll Forward]
Balance at beginning of period	$ (153)
Change in fair value	4
Balance at end of period	$ (157)
Acquisition Related Contingent Consideration [Member] \| Minimum \| Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Weighted average cost of capital	10.00%
Acquisition Related Contingent Consideration [Member] \| Maximum \| Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Weighted average cost of capital	21.00%

Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax expense	$ 24	$ 51
Effective tax rate (percent)	12.40%	35.80%

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2017	Mar. 31, 2016
Income Tax Contingency [Line Items]
Effective income tax rate reconciliation, distribution of earnings from foreign partnership (percent)		19.00%
Income tax expense	$ 24	$ 51
Effective tax rate (percent)	12.40%	35.80%

Defined Benefit Plans (Schedule of Components of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Total net periodic benefit cost	$ 2	$ 2

Facility Lease Obligations (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 2012	Mar. 31, 2017	Dec. 31, 2016
Operating Leased Assets [Line Items]
Facility lease obligation		$ 270	$ 233
CONNECTICUT \| Facility Lease Obligation
Operating Leased Assets [Line Items]
Facility lease obligation		135	136
Minimum \| CONNECTICUT \| Construction in Progress
Operating Leased Assets [Line Items]
Renewal term (years)	10 years
Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded unconditional purchase obligation, purchases		29
Lonza Group AG \| Facility Lease Obligation
Operating Leased Assets [Line Items]
Facility lease obligation		$ 142	107
Facility lease obligation, payment period (years)		10 years
Lonza Group AG \| Construction in Progress
Operating Leased Assets [Line Items]
Property, plant and equipment, gross		$ 158	$ 118
Inventories \| Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded unconditional purchase obligation, purchases		25
Facility Lease Obligation \| Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded unconditional purchase obligation, purchases		$ 4

Commitments and Contingencies (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($)
Commitments and Contingencies [Line Items]
Other Commitment, Potential Payment	$ 27
Arbutus Agreement [Member]
Commitments and Contingencies [Line Items]
Research and development expense, upfront payment	8
Research and development arrangement, potential payment	75
Lonza Agreement [Member]
Commitments and Contingencies [Line Items]
Remaining total commitments with Lonza	$ 1,126

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
Restructuring (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 24
Restructuring Reserve	21		$ 0
Employee Separation Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	21
Restructuring Reserve	21		$ 0
Relocation of European Headquarters [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, additional restructuring costs	$ 24
Minimum \| Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		$ 5
Maximum \| Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses		$ 10

Restructuring Reserve Roll Forward (Details) $ in Millions	3 Months Ended
Restructuring Reserve Roll Forward (Details) $ in Millions	Mar. 31, 2017 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 0
Restructuring expenses	24
Cash settlements	0
Adjustments to previous estimates	0
Restructuring Reserve, Asset Impairment	(3)
Ending Balance	21
Employee Separation Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Restructuring expenses	21
Cash settlements	0
Adjustments to previous estimates	0
Restructuring Reserve, Asset Impairment	0
Ending Balance	21
Contract Termination Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Restructuring expenses	0
Cash settlements	0
Adjustments to previous estimates	0
Restructuring Reserve, Asset Impairment	0
Ending Balance	0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Restructuring expenses	3
Cash settlements	0
Adjustments to previous estimates	0
Restructuring Reserve, Asset Impairment	(3)
Ending Balance	$ 0

Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 132	$ 129
Money Market Funds [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	32	266
Money Market Funds [Member] \| Cash Equivalents [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Money Market Funds [Member] \| Cash Equivalents [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	32	266
Money Market Funds [Member] \| Cash Equivalents [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Commercial Paper [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	17	70
Commercial Paper [Member] \| Cash Equivalents [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Commercial Paper [Member] \| Cash Equivalents [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	17	70
Commercial Paper [Member] \| Cash Equivalents [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Commercial Paper [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	21	44
Commercial Paper [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Commercial Paper [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	21	44
Commercial Paper [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Corporate Bond Securities [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	12	10
Corporate Bond Securities [Member] \| Cash Equivalents [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Corporate Bond Securities [Member] \| Cash Equivalents [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	12	10
Corporate Bond Securities [Member] \| Cash Equivalents [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Corporate Bond Securities [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	375	113
Corporate Bond Securities [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Corporate Bond Securities [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	375	113
Corporate Bond Securities [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Mutual Funds [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	17	13
Mutual Funds [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	17	13
Mutual Funds [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Mutual Funds [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Municipal Bonds [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	14	40
Municipal Bonds [Member] \| Cash Equivalents [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Municipal Bonds [Member] \| Cash Equivalents [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	14	40
Municipal Bonds [Member] \| Cash Equivalents [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Municipal Bonds [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1	51
Municipal Bonds [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Municipal Bonds [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1	51
Municipal Bonds [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Other Government Obligations [Member] \| Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	14
Other Government Obligations [Member] \| Cash Equivalents [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0
Other Government Obligations [Member] \| Cash Equivalents [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	14
Other Government Obligations [Member] \| Cash Equivalents [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0
Other Government Obligations [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	323	100
Other Government Obligations [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Other Government Obligations [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	323	100
Other Government Obligations [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Certificates of Deposit [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	11	5
Certificates of Deposit [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Certificates of Deposit [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	11	5
Certificates of Deposit [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Equity Securities [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1	1
Equity Securities [Member] \| Marketable Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1	1
Equity Securities [Member] \| Marketable Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Equity Securities [Member] \| Marketable Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	65	97
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	65	97
Foreign Exchange Forward [Member] \| Prepaid expenses and other current assets \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] \| Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	43	59
Foreign Exchange Forward [Member] \| Other assets \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] \| Other assets \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	43	59
Foreign Exchange Forward [Member] \| Other assets \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Interest Rate Contract [Member] \| Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	10	10
Interest Rate Contract [Member] \| Other assets \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0	0
Interest Rate Contract [Member] \| Other assets \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	10	10
Interest Rate Contract [Member] \| Other assets \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0	0
Interest Rate Contract [Member] \| Prepaid expenses and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	2
Interest Rate Contract [Member] \| Prepaid expenses and other current assets \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0
Interest Rate Contract [Member] \| Prepaid expenses and other current assets \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	2
Interest Rate Contract [Member] \| Prepaid expenses and other current assets \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0
Foreign Exchange Forward [Member] \| Other current liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	14	12
Foreign Exchange Forward [Member] \| Other current liabilities \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] \| Other current liabilities \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	14	12
Foreign Exchange Forward [Member] \| Other current liabilities \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] \| Other liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	9	4
Foreign Exchange Forward [Member] \| Other liabilities \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] \| Other liabilities \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	9	4
Foreign Exchange Forward [Member] \| Other liabilities \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Acquisition Related Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	157
Acquisition Related Contingent Consideration [Member] \| Current portion of contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	25	24
Acquisition Related Contingent Consideration [Member] \| Current portion of contingent consideration \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Acquisition Related Contingent Consideration [Member] \| Current portion of contingent consideration \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Acquisition Related Contingent Consideration [Member] \| Current portion of contingent consideration \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	25	24
Acquisition Related Contingent Consideration [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	132	129
Acquisition Related Contingent Consideration [Member] \| Contingent Consideration [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Acquisition Related Contingent Consideration [Member] \| Contingent Consideration [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Acquisition Related Contingent Consideration [Member] \| Contingent Consideration [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 132	$ 129